Abstract
Background Reducing HIV transmission using pre-exposure prophylaxis (PrEP) requires targeting individuals at high acquisition risk, such as men who have sex with men (MSM) with a history of non-occupational post-exposure prophylaxis (nPEP). This study aims to characterize longitudinal trends in PrEP uptake and its determinants among nPEP users in Montréal.
Methods Eligible attendees at Clinique médicale l’Actuel were recruited prospectively starting in October 2000 (nPEP) and January 2013 (PrEP). Linking these cohorts, we characterized the PEP-to-PrEP cascade, examined the determinants of PrEP uptake after nPEP consultation using a Cox proportional-hazard model, and assessed whether PrEP persistence differed by nPEP history using Kaplan-Meier curves.
Results As of August 2019, 31% of 2,682 MSM nPEP cohort participants had two or more nPEP consultations. Subsequent PrEP consultations occurred among 36% of nPEP users, of which 17% sought nPEP again afterwards. Among 2,718 PrEP cohort participants, 46% reported previous nPEP use. Among nPEP users, those aged 25-49 years (Hazard Ratio (HR)=1.3, 95% confidence interval (CI): 1.1-1.7), with more nPEP episodes (HR=1.4, 95%CI: 1.3-1.5), reported chemsex (HR=1.3, 95%CI: 1.1-1.7), with a STI history (HR=1.5; 95%CI: 1.3-1.7), and who returned for their first nPEP follow-up visit (HR=3.4, 95%CI: 2.7-4.2) had higher rates of PrEP linkage. There was no difference in PrEP persistence between PEP-to-PrEP and PrEP only participants.
Conclusion Over one-third of nPEP users were subsequently prescribed PrEP. However, the large proportion of men who repeatedly use nPEP calls for more efficient PrEP-linkage services and, among those that use PrEP, improved persistence should be encouraged.
Competing Interest Statement
In the past years l’Actuel PrEP databank has received funding from ViiV Healthcare (2016) and Gilead Sciences Inc. (2018, 2019). L’Actuel PEP databank has received funding from ViiV Healthcare (2016). MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc. outside of the submitted work and contractual arrangements from both the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS), also outside of the submitted work.
Funding Statement
This work was supported by the Canadian Foundation for AIDS Research and the Canadian Institutes of Health Research. MM-G’s research programs was funded by career awards from the Fonds de recherche du Québec - Santé.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conference presentation: This paper will be presented at the 29th Annual Canadian Conference on HIV / AIDS Research; May 2020; Québec city, QC, Canada.
Funding: This work was supported by the Canadian Foundation for AIDS Research and the Canadian Institutes of Health Research. MM-G’s research programs was funded by career awards from the Fonds de recherche du Québec – Santé.
Conflict of Interest Statement: In the past years l’Actuel PrEP databank has received funding from ViiV Healthcare (2016) and Gilead Sciences Inc. (2018, 2019). L’Actuel PEP databank has received funding from ViiV Healthcare (2016). MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc. outside of the submitted work and contractual arrangements from both the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS), also outside of the submitted work.
Data Availability
The data that support the findings of this study are available from Clinique Medicale l'Actuel but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.
